]>
IRCT20200205046380N2 IRCT 2020-09-20 Shahid Beheshti University of Medical Sciences Evaluation of the therapeutic efficacy of injectable 5FU solution for basal cell carcinoma in patients referred to Loghman Hakim and Shohada-e Tajrish hospitals between 2020 and 2021 Evaluation of the therapeutic efficacy of injectable 5FU solution for basal cell carcinoma in patients referred to Loghman Hakim and Shohada-e Tajrish hospitals between 2020 and 2021 2020-04-04 anticipated 50 Complete https://irct.ir/trial/46895 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Randomization description: The non-random sampling is a method for sampling.This means that all patients with BCC will be eligible to study. 2 Basal cell carcinoma. Intervention group: 1-2 ml of the 50mg/ml 5FU solution (Kavosh Gostar Darou, Iran) will be injected in to the BCC lesion once a week until the resolution of the lesion or for a maximum duration of 6 weeks.. Yes - There is a plan to make this available What will be shared: Information about the timing of diagnosis of disease,The type of lesion is based on the histology, the duration of the lesion, and the anatomical location of the lesion,Patient's gender and age, response rate based on observation of complete improvement or reduction of lesion size,Information about side effects of drug When: The data can be accessed after the publication of the results To whom: People working in academic and scientific institutions Conditions: Data can only be used to improve individuals' disease condition. Where to obtain: Dr. Khatere Zahedi 00989132154819 khaterezahedi4819@gmail.com How to obtain: Request via email with complete identification data of the individual, the institution he/she works in, thorough explanation of the reason of the request. Data can be accessed after investigation of the responsible agent. Comments:
public Khetere Zahedi
SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak, Tehran, Iran
Tehran Iran (Islamic Republic of) 1436943415 002188045103 khaterezahedi4819@gmail.com Shahid Beheshti University of Medical Sciences scientific Khatere Zahedi
SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak, Tehran, Iran
Tehran Iran (Islamic Republic of) 14369-43415 +98 21 8804 5103 khaterezahedi@sbmu.ac.ir Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) People with BCC who are willing to participate in the study People with BCC who can go to the clinic for visiting no limit no limit Both Recurrent BCC Very large BCC (larger than 2 cm) BCC around the eyes Patients with lymphoma or leukemia or immunodeficiency or in pregnant or lactating patients C44.01 Basal cell carcinoma of skin of lip Treatment - Drugs Intervention group: 1-2 ml of the 50mg/ml 5FU solution (Kavosh Gostar Darou, Iran) will be injected in to the BCC lesion once a week until the resolution of the lesion or for a maximum duration of 6 weeks. Assessment the complete improvement or shrinkage of the lesion. Timepoint: Weekly until the healing of lesion or up to 6 weeks. Method of measurement: Observation and questionnaire. Evaluation of response to treatment based on initial size, anatomical location, pathology type, and duration of lesion formation and investigation the response to treatment based on age and gender. Timepoint: Weekly until the healing of lesion or up to 6 weeks. Method of measurement: Observation and questionnaire. Shahid Beheshti University of Medical Sciences Approved 2019-12-17 Research Ethics Committee of Skin Research Center - Shahid Beheshti University of Medical Sciences Shohada-E-Tajrish hospital, Qods Sq., Tehran, Iran Tehran Tehran Iran (Islamic Republic of)